Here’s what you should know:
1. Nine analysts gave Envision Healthcare, trading under the symbol EVHC, a “buy” rating and one gave the company a “strong buy” rating. On the contrary, one analyst issued a “sell” rating, while six others issued “hold” ratings.
2. Credit Suisse Group was the most recent firm to analyze the stock, issuing an “outperform” rating Dec. 11.
3. The analysts’ consensus target price is $47.57.
4. Envision hit a 52-week low of $23.77 in November. As of Dec. 11 at 11 a.m., Envision was trading at $32.57. Its 52-week high stands at $73.
More articles on transactions/valuations:
Physicians, Bingham Memorial Hospital collaborate on Idaho-based Cardio Renal Centers of America: 4 key notes
75 ASCs, outpatient centers opened and announced in 2017
9 hospitals, health systems opening or planning ASCs — November 2017
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
